Thesis
NVG-291 enters registrational RESTORE study in chronic tetraplegia; thesis resolves on whether Phase 2 neural recovery signals replicate at scale
NVG-291, a PTPσ inhibitor targeting neural regeneration, is entering the RESTORE registrational study in chronic tetraplegia patients with established spinal cord injury. The thesis turns on whether RESTORE replicates the statistically significant biomechanical gait improvements seen in CONNECT SCI at registrational scale and satisfies FDA's endpoint requirements. The primary risks are competitive pressure from rehabilitation-focused approaches and the absence of any approved disease-modifying SCI therapy as a regulatory comparator, which cuts both ways on approvability standards.
Focus
RESTORE registrational study initiation for NVG-291
mid-2026
Bull
A positive outcome is RESTORE enrolling on schedule with a well-powered, FDA-aligned design that preserves the composite neural recovery endpoint architecture validated in CONNECT SCI, where 100% of NVG-291 subjects were classified as responders versus 10% for placebo. If the registrational study launches with these parameters intact and early enrollment milestones are met, it would confirm that the Phase 2 biomechanical and speed-effort dissociation signals are reproducible and that regulators view the endpoint construct as approvable, substantially de-risking the path to NDA submission.
Bear
The most significant failure mode is enrollment difficulty in chronic tetraplegia, a small and heterogeneous population where patient identification, site activation, and retention are historically challenging, which could delay or underpowered the study. A secondary risk is that the FDA-aligned endpoint construct — particularly the biomechanical composite measuring neural recovery rather than conventional functional scales — proves difficult to standardize across registrational sites, introducing measurement noise that dilutes effect size relative to the tightly controlled Phase 1b/2a setting.
Unlock the full thesis for NGEN.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialGenerated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.